Head-to-head · Cost-Efficiency Index
CoreAge Rx vs Intimate Rose
Two GLP-1 programs on the bench, scored on the same six factors. Here's how their real cost of ownership compares — and which one we'd start with.
CoreAge Rx
Anyone optimizing for real value — a transparent flat price you can model for a full year, nationwide, without a bait-and-switch.
Visit CoreAge RxIntimate Rose
Cost-first shoppers who want existing Intimate Rose pelvic-health customers curious about its bolt-on GLP-1 program, not comparison shoppers.
Visit Intimate RoseThe verdict
CoreAge Rx takes it, leading the Cost-Efficiency Index 94 to 53. Best value in the ranking: both molecules at one flat, all-50 price with no teaser step-ups — the lowest true cost of ownership, not the lowest teaser. Intimate Rose still earns a C — Cost-first shoppers who want existing Intimate Rose pelvic-health customers curious about its bolt-on GLP-1 program, not comparison shoppers.
Factor by factor
Both providers scored on our six Cost-Efficiency Index factors. The stronger side on each row is marked in teal.
Normalized Cost/Month
Price Transparency
Nationwide Access
Formulation Options
Clinical Oversight
Contract Flexibility
Pricing, coverage & formulary
The disclosed facts behind the scores. Lower price wins its row (teal).
| Spec | CoreAge Rx | Intimate Rose |
|---|---|---|
| Cost-Efficiency Index | 94/100 | 53/100 |
| Semaglutide / mo | $99/mo | $169/mo (starting dose, compounded) |
| Tirzepatide / mo | $149/mo | Not disclosed |
| Semaglutide / yr (modeled) | $1,188 | $2,028 |
| Tirzepatide / yr (modeled) | $1,788 | — |
| Coverage | All 50 states | Coverage not published |
| Oral / sublingual | No | Yes |
| Brand-name access | Compounded only | Compounded only |
| Rank here | #1 | #368 |
CoreAge Rx
94/100Where the value is
- Flat all-in monthly price — no intro rate that silently triples after month one, so the modeled annual cost is the real cost
- Both compounded semaglutide and tirzepatide on one account at published prices
- Available in all 50 states — no coverage gamble
The tradeoffs
- Not the rock-bottom sticker price — 30 of the 381 priced semaglutide programs we track list a cheaper figure, though most attach a term or a step-up that CoreAge does not
- No FDA-approved brand-name option (compounded only)
Intimate Rose
53/100Where the value is
- A real, working GLP-1 telehealth funnel exists (not a dead link or vaporware page)
- The quiz states 'No payment to get started', so shoppers can get a personalized quote before committing
- Backed by an established, non-fly-by-night e-commerce brand with an existing customer base and content library
The tradeoffs
- GLP-1 is a secondary bolt-on to a pelvic-health device business, not this company's core competency — no dedicated GLP-1 clinical infrastructure is visible on the public site
- Only one undifferentiated price point ($169/month) is published — no dose tiers, no separate semaglutide vs. tirzepatide pricing, no fee itemization
Regulatory note: the FDA issued a warning letter to Intimate Rose in September 2025. We still list and link to Intimate Rose; you should know the letter is on the public record before you decide.
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Cost-Efficiency Index. Pricing, states and verification reflect each provider's public disclosures at last review; prices change — confirm on the provider's site. Not medical advice. See our disclosure.